Literature DB >> 23140758

A review investigating the effect of allopurinol on the progression of kidney disease in hyperuricemic patients with chronic kidney disease.

Samaneh Kabul, Brian Shepler.   

Abstract

This communication provides a brief report on the studies evaluating the use of allopurinol for delay of kidney disease progression and a discussion of the current limitations and future research needed. To date, only 5 studies have reported a delay in the progression of kidney disease with allopurinol use; a sixth study is currently underway. Allopurinol does seem to delay the progression of kidney disease as measured by using serum creatinine and glomerular filtration rates in hyperuricemic patients with chronic kidney disease. However, randomized, double-blind, placebo-controlled trials enrolling more patients and controlling for confounding variables are needed to confirm these findings. Published by EM Inc USA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23140758     DOI: 10.1016/j.clinthera.2012.10.008

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  6 in total

1.  A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial.

Authors:  George L Bakris; Hidetaka Mikami; Masayuki Hirata; Akihiro Nakajima; Michael D Cressman
Journal:  Kidney360       Date:  2021-06-30

Review 2.  Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis.

Authors:  Usman A Khan; Amit X Garg; Chirag R Parikh; Steven G Coca
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

Review 3.  Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.

Authors:  Anna Pisano; Valeria Cernaro; Guido Gembillo; Graziella D'Arrigo; Michele Buemi; Davide Bolignano
Journal:  Int J Mol Sci       Date:  2017-10-31       Impact factor: 5.923

4.  Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study.

Authors:  Sylvie Perreault; Javier Nuevo; Scott Baumgartner; Robert Morlock
Journal:  World J Nephrol       Date:  2017-05-06

Review 5.  The impact of antihypertensives on kidney disease.

Authors:  Diego F Marquez; Gema Ruiz-Hurtado; Luis Ruilope
Journal:  F1000Res       Date:  2017-05-02

6.  Effect of febuxostat on blood pressure in hyperuricemic patients: A protocol for a systematic review and meta-analysis.

Authors:  Jia Yao; Xiaoyan Shi; Simin Fan; Yang Gao; Hengchang Hu; PanPan Wang; Qiu Chen
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.